

*** NOTICES ***

JPO and INPIT are not responsible for any damages caused by the use of this translation.

1. This document has been translated by computer. So the translation may not reflect the original precisely.
2. **** shows the word which can not be translated.
3. In the drawings, any words are not translated.

MEANS

[Means for Solving the Problem] This invention is an osteoporosis treating agent containing EPA-E as an active principle.

[0009] When this invention person inquired wholeheartedly about a safe remedy to osteoporosis, he found out that EPA-E is very useful to prevention and an improvement of advance of a clinical top and osteoporosis, and that it was useful in especially an I-beam. In this invention, prevention of the disease concerned is also included with a therapy.

[0010] Hereafter, this invention is explained in detail.

[0011] EPA-E in this invention refers to all the - ****- 5, 8, 11, and 14 and 17-ethyl icosapentate (ethyl all-cis-5, 8, 11 and 14, 17-icosapentaenoate), It can obtain by carrying out fish oil besides a commercial item by the ability to carry out refining and esterification treatment by a publicly known method.

[0012] in an active principle of a treating agent of this invention, EPA-E can use the pure article -- of course -- a fatty acid content -- 85 % of the weight or more can also use a thing of EPA-E preferably 50% of the weight or more.

[0013] A class of a suitable carrier or a medium which a treating agent of this invention prescribes an active principle for the patient with a compound independent, or is generally used, An excipient, a binding material, lubricant, colorant, a flavor agent, and if needed For example, sterilized water and vegetable oil, an innocence organic solvent or an innocence solubilizing agent (for example, glycerin, propylene glycol), an emulsifier, a suspending agent (for example, Tween 80, a gum arabic solution), etc. -- suitably -- selection ***** -- it can prepare to suitable pharmaceutical preparation for medicines.

[0014] As for the above-mentioned pharmaceutical preparation, since EPA-E is highly unsaturated, it is desirable to make quinone and alpha-tocopherol which approve as an anti-oxidant, for example, butyrate-ized hydroxytoluene, butyrate-ized hydroxyanisole, propyl gallate, and medicine and in which it deals further contain.